Advanced search
1 file | 521.53 KB

Incorporating PARP-inhibitors into clinical routine : a tailored treatment strategy to tackle ovarian cancer

Emiel De Jaeghere (UGent) , Katrien Vandecasteele (UGent) , Kathleen Claes (UGent) , Amin Makar (UGent) , Philippe Tummers (UGent) , Veronique Cocquyt (UGent) and Hannelore Denys (UGent)
(2017) ACTA CLINICA BELGICA. 72(1). p.6-11
Author
Organization
Abstract
DNA repair mechanisms play a key role in oncogenesis and cancer progression in women with BRCA mutation-positive (BRCAm) ovarian cancer (OC). The BRCA1/2 and poly(ADP-ribose) polymerase (PARP) proteins are considered the foremost mediators among the various components of double-strand and single-strand repair, respectively. A series of new therapeutic drugs that target PARP have been developed for BRCAm OC. This class of agents provokes tumour-specific cytotoxicity with minimal side effects by inducing synthetic lethality, of which they are the first clinical example. The European Medicines Agency granted accelerated licensing approval for the first-in-class-drug that inhibits PARP, olaparib (Lynparza, AstraZeneca). Olaparib can be used as a monotherapeutic maintenance treatment in patients with platinum-sensitive relapsed (germline and/or somatic) BRCAm high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer responsive to platinum-based chemotherapy. Seen in light of these recent events, this review article will focus on (a) how PARP-inhibitors exploit cancer-specific defects in the homologous recombination repair apparatus and (b) how BRCA testing is implemented in routine clinical care.
Keywords
PARP-inhibitors, Olaparib, BRCA, Ovarian cancer, Targeted therapy, RIBOSE POLYMERASE INHIBITORS, OLAPARIB MAINTENANCE THERAPY, POLY(ADP-RIBOSE) POLYMERASE, HOMOLOGOUS RECOMBINATION, SOMATIC MUTATIONS, PHASE-2 TRIAL, BRCA STATUS, REPAIR, TUMORS, CELLS

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 521.53 KB

Citation

Please use this url to cite or link to this publication:

Chicago
De Jaeghere, Emiel, Katrien Vandecasteele, Kathleen Claes, Amin Makar, Philippe Tummers, Veronique Cocquyt, and Hannelore Denys. 2017. “Incorporating PARP-inhibitors into Clinical Routine : a Tailored Treatment Strategy to Tackle Ovarian Cancer.” Acta Clinica Belgica 72 (1): 6–11.
APA
De Jaeghere, E., Vandecasteele, K., Claes, K., Makar, A., Tummers, P., Cocquyt, V., & Denys, H. (2017). Incorporating PARP-inhibitors into clinical routine : a tailored treatment strategy to tackle ovarian cancer. ACTA CLINICA BELGICA, 72(1), 6–11.
Vancouver
1.
De Jaeghere E, Vandecasteele K, Claes K, Makar A, Tummers P, Cocquyt V, et al. Incorporating PARP-inhibitors into clinical routine : a tailored treatment strategy to tackle ovarian cancer. ACTA CLINICA BELGICA. 2017;72(1):6–11.
MLA
De Jaeghere, Emiel, Katrien Vandecasteele, Kathleen Claes, et al. “Incorporating PARP-inhibitors into Clinical Routine : a Tailored Treatment Strategy to Tackle Ovarian Cancer.” ACTA CLINICA BELGICA 72.1 (2017): 6–11. Print.
@article{7243968,
  abstract     = {DNA repair mechanisms play a key role in oncogenesis and cancer progression in women with BRCA mutation-positive (BRCAm) ovarian cancer (OC). The BRCA1/2 and poly(ADP-ribose) polymerase (PARP) proteins are considered the foremost mediators among the various components of double-strand and single-strand repair, respectively. A series of new therapeutic drugs that target PARP have been developed for BRCAm OC. This class of agents provokes tumour-specific cytotoxicity with minimal side effects by inducing synthetic lethality, of which they are the first clinical example. The European Medicines Agency granted accelerated licensing approval for the first-in-class-drug that inhibits PARP, olaparib (Lynparza, AstraZeneca). Olaparib can be used as a monotherapeutic maintenance treatment in patients with platinum-sensitive relapsed (germline and/or somatic) BRCAm high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer responsive to platinum-based chemotherapy. Seen in light of these recent events, this review article will focus on (a) how PARP-inhibitors exploit cancer-specific defects in the homologous recombination repair apparatus and (b) how BRCA testing is implemented in routine clinical care.},
  author       = {De Jaeghere, Emiel and Vandecasteele, Katrien and Claes, Kathleen and Makar, Amin and Tummers, Philippe and Cocquyt, Veronique and Denys, Hannelore},
  issn         = {1784-3286},
  journal      = {ACTA CLINICA BELGICA},
  keyword      = {PARP-inhibitors,Olaparib,BRCA,Ovarian cancer,Targeted therapy,RIBOSE POLYMERASE INHIBITORS,OLAPARIB MAINTENANCE THERAPY,POLY(ADP-RIBOSE) POLYMERASE,HOMOLOGOUS RECOMBINATION,SOMATIC MUTATIONS,PHASE-2 TRIAL,BRCA STATUS,REPAIR,TUMORS,CELLS},
  language     = {eng},
  number       = {1},
  pages        = {6--11},
  title        = {Incorporating PARP-inhibitors into clinical routine : a tailored treatment strategy to tackle ovarian cancer},
  url          = {http://dx.doi.org/10.1080/17843286.2016.1188455},
  volume       = {72},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: